Monopar Therapeutics

Yahoo Finance • 29 days ago

Monopar therapeutics director Tsuchimoto sells $356k in stock

Director Kim R. Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR), sold 8,904 shares of common stock on July 14, 2025. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, netting approximately $356,170. Th... Full story

Yahoo Finance • 29 days ago

Monopar therapeutics director Starr sells $672k in stock

Christopher M. Starr, a director at Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025. The company’s stock has shown remarkable performance, with a 1,057% return over the past year, according to Invest... Full story

Yahoo Finance • 29 days ago

Monopar therapeutics CEO Chandler Robinson sells $672k in stock

Chandler Robinson, Chief Executive Officer of Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025, according to a recent SEC Filing. The shares were sold at prices ranging from $40.00 to $40.25, for a to... Full story

Yahoo Finance • 2 months ago

Chardan initiates Monopar stock with buy rating on Wilson disease drug

Investing.com - Chardan Capital Markets initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a buy rating and a $60 price target, citing potential in its late-stage Wilson disease treatment and early-stage radiopharmaceutical pipe... Full story

Yahoo Finance • 2 months ago

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatme... Full story

Yahoo Finance • 2 months ago

Monopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%

Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) will be added [https://seekingalpha.com/pr/20123970-monopar-therapeutics-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes] to the broad-market Russel... Full story

Yahoo Finance • 3 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today... Full story

Yahoo Finance • 6 months ago

Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Monopar Therapeutics Inc (NASDAQ:MNPR) stands against the other healthcare stocks. The... Full story

Yahoo Finance • 2 years ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announ... Full story

Yahoo Finance • 2 years ago

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life... Full story

Yahoo Finance • 2 years ago

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittad... Full story

Yahoo Finance • 2 years ago

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Rob... Full story

Yahoo Finance • 2 years ago

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced a collaboration with the Cance... Full story

Yahoo Finance • 2 years ago

Monopar to Participate in the Radiopharma Forum by the Lake 2023

WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinso... Full story

Yahoo Finance • 2 years ago

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler Robinso... Full story

Yahoo Finance • 2 years ago

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

WILMETTE, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical­stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or impr... Full story

Yahoo Finance • 2 years ago

Monopar to Present at the Jefferies Radiopharma Innovation Summit

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life... Full story

Yahoo Finance • 2 years ago

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

WILMETTE, Ill., March 27, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life... Full story

Yahoo Finance • 2 years ago

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Validive® Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m2) WILMETTE, Ill., March 23, 2023 (GLOBE NEWSWIRE) -- Mon... Full story

Yahoo Finance • 2 years ago

Monopar to Present at the 35th Annual Roth Conference

WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life... Full story